A groundbreaking development in the treatment of metabolic liver disease and fibrosis has been unveiled by McMaster University researchers. A new drug candidate has shown promising results in reversing these debilitating conditions, according to pre-clinical data. The innovative compound targets the root causes of metabolic liver disease and fibrosis, offering hope for effective treatment options in the future. Current treatments manage symptoms but seldom address the disease’s progression. The research demonstrates the drug’s potential to halt and even reverse liver damage, marking a significant shift in therapeutic approaches. As metabolic liver diseases become increasingly prevalent, this discovery could signal a transformative step in patient care. Researchers are optimistic about advancing to clinical trials, paving the way for potentially crucial medical breakthroughs in liver health.
McMaster NewsNew data shows homelessness in Northern Ontario surging beyond community capabilities
January 14, 2026
New data highlights a troubling increase in homelessness in Northern Ontario, outpacing the resources that local communities can mobilize to address the crisis. According to